Analyst Jill Wu from CMB International Securities maintained a Buy rating on CSPC Pharmaceutical Group and decreased the price target to HK$11.05 from HK$12.11.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jill Wu’s rating is based on CSPC Pharmaceutical Group’s strategic business development initiatives and their potential to drive long-term growth. The company has shown a mild recovery in sales in the third quarter of 2025, with a notable increase in core revenue, excluding business development income. This growth is supported by stable drug sales and a significant reduction in selling expenses.
Additionally, CSPC’s commitment to research and development, as evidenced by increased R&D investments, positions the company well for future advancements. The sustainable income stream from out-licensing agreements across a diverse portfolio further strengthens CSPC’s financial outlook. The promising development of their EGFR ADC asset, SYS6010, with upcoming data readouts, adds to the potential for meaningful out-licensing opportunities, reinforcing the Buy rating.